OBJECTIVE: We aimed to evaluate the protective role of partial versus total splenectomy against sepsis in patients with thalassaemia when other preventive measures are not available. Overwhelming postsplenectomy infection is a serious complication of splenectomy in these patients, and most present with pneumococcal septicemia. Pneumococcal vaccine given before surgery is a well-established preventive measure. METHODS: In this study, we compared 2 populations of patients from Iraq and Saudi Arabia, both of whom underwent splenectomy for thalassaemia. All patients from Saudi Arabia were given a preoperative pneumococcal vaccine and underwent total splenectomy after about 4 weeks. Unfortunately, this vaccine was not available for the Iraqi patients. Partial splenectomy was offered to many of these patients as a protective measure against this fatal complication. RESULTS: A significant difference was found between the total splenectomy fatalities in the 2 groups. There were 5 deaths in the 30 enrolled Iraqi patients over 4 years. One death over a 12-year period was reported in the 22 patients from Saudi Arabia. Partial splenectomy was associated with a dramatic reduction of mortality in the Iraqi patients. None of the 12 patients died during a follow-up period of 4 years. CONCLUSIONS: Pneumovax is a powerful prophylactic tool against overwhelming postsplenectomy infection in patients with thalassaemia and should be used whenever available. In poor or problematic countries with limited health resources, partial rather than total splenectomy could offer an alternative measure to avoid this fatal complication.
OBJECTIVE: We aimed to evaluate the protective role of partial versus total splenectomy against sepsis in patients with thalassaemia when other preventive measures are not available. Overwhelming postsplenectomy infection is a serious complication of splenectomy in these patients, and most present with pneumococcal septicemia. Pneumococcal vaccine given before surgery is a well-established preventive measure. METHODS: In this study, we compared 2 populations of patients from Iraq and Saudi Arabia, both of whom underwent splenectomy for thalassaemia. All patients from Saudi Arabia were given a preoperative pneumococcal vaccine and underwent total splenectomy after about 4 weeks. Unfortunately, this vaccine was not available for the Iraqi patients. Partial splenectomy was offered to many of these patients as a protective measure against this fatal complication. RESULTS: A significant difference was found between the total splenectomy fatalities in the 2 groups. There were 5 deaths in the 30 enrolled Iraqi patients over 4 years. One death over a 12-year period was reported in the 22 patients from Saudi Arabia. Partial splenectomy was associated with a dramatic reduction of mortality in the Iraqi patients. None of the 12 patients died during a follow-up period of 4 years. CONCLUSIONS: Pneumovax is a powerful prophylactic tool against overwhelming postsplenectomy infection in patients with thalassaemia and should be used whenever available. In poor or problematic countries with limited health resources, partial rather than total splenectomy could offer an alternative measure to avoid this fatal complication.
Authors: Henry E Rice; Keith T Oldham; Cheryl A Hillery; Michael A Skinner; Sara M O'Hara; Russell E Ware Journal: Ann Surg Date: 2003-02 Impact factor: 12.969
Authors: B Bader-Meunier; F Gauthier; F Archambaud; T Cynober; F Miélot; J P Dommergues; J Warszawski; N Mohandas; G Tchernia Journal: Blood Date: 2001-01-15 Impact factor: 22.113
Authors: Sigurdur Y Kristinsson; Gloria Gridley; Robert N Hoover; David Check; Ola Landgren Journal: Haematologica Date: 2013-09-20 Impact factor: 9.941
Authors: B Serio; L Pezzullo; V Giudice; R Fontana; S Annunziata; I Ferrara; R Rosamilio; C De Luca; M Rocco; N Montuori; C Selleri Journal: Transl Med UniSa Date: 2013-05-06
Authors: Goda Juzenaite; Judith Secklehner; Juho Vuononvirta; Yoseph Helbawi; John B G Mackey; Charlotte Dean; James A Harker; Leo M Carlin; Sara Rankin; Katia De Filippo Journal: Front Immunol Date: 2021-04-19 Impact factor: 7.561